ClinicalTrials.gov

History of Changes for Study: NCT04023227
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC (PARACHUTE-HF)
Latest version (submitted December 2, 2021) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 July 16, 2019 None (earliest Version on record)
2 March 10, 2020 Recruitment Status, Study Status, Contacts/Locations and Oversight
3 April 9, 2020 Study Status and Contacts/Locations
4 April 10, 2020 Recruitment Status, Study Status and Contacts/Locations
5 July 7, 2020 Recruitment Status, Study Status and Contacts/Locations
6 November 10, 2020 Study Status
7 March 30, 2021 Study Status and IPDSharing
8 December 2, 2021 Study Status and Contacts/Locations
Comparison Format:

Scroll up to access the controls

Study NCT04023227
Submitted Date:  July 16, 2019 (v1)

Open or close this module Study Identification
Unique Protocol ID: CLCZ696B3302
Brief Title: Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC (PARACHUTE-HF)
Official Title: A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomyopathy
Secondary IDs:
Open or close this module Study Status
Record Verification: July 2019
Overall Status: Not yet recruiting
Study Start: December 16, 2019
Primary Completion: December 16, 2022 [Anticipated]
Study Completion: December 16, 2022 [Anticipated]
First Submitted: July 10, 2019
First Submitted that
Met QC Criteria:
July 16, 2019
First Posted: July 17, 2019 [Actual]
Last Update Submitted that
Met QC Criteria:
July 16, 2019
Last Update Posted: July 17, 2019 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Novartis Pharmaceuticals
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: The purpose of this study is to evaluate the effect of sacubitril/valsartan 200 mg BID compared with enalapril 10 mg BID, in addition to conventional heart failure (HF) treatment, in improving a hierarchical composite of cardiovascular (CV) events (i.e. CV death or the occurrence of first HF hospitalization) and causing a greater reduction in n terminal prohormone of brain natriuretic peptide (NT-proBNP, at Week 12 from Baseline) in participants with HF with reduced ejection fraction (HFrEF) caused by CCC.
Detailed Description:
Open or close this module Conditions
Conditions: Chagas Disease
Heart Failure
Keywords: Chagas' disease
heart failure
angiotensin receptor-neprilysin inhibitor
ARNI
ARB
ACEI
sacubitril/valsartan
enalapril
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 4
Interventional Study Model: Parallel Assignment
This is a Phase 4, multinational, multicenter, parallel-group, prospective, randomized, open-label, blinded-endpoint adjudication, active-controlled study to demonstrate superiority of sacubitril/valsartan over enalapril in improving a composite of CV events (CV death or first HF hospitalization), or in causing greater reduction or lesser increase in NT-proBNP levels at Week 12 in participants with HFrEF caused by CCC.
Number of Arms: 2
Masking: Single (Outcomes Assessor)
Allocation: Randomized
Enrollment: 900 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Sacubitril/valsartan

Sacubitril/valsartan 200 mg b.i.d.

Following randomization, patients will receive sacubitril/valsartan in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).

Participants taking ACEIs who are randomized to sacubitril/valsartan will do a 36-hour ACEI washout before they start taking the study drug

Sacubitril/valsartan in dose levels of 50 mg, 100 mg, and 200 mg are equivalent to sacubitril/valsartan 24/26 mg, 49/51 mg and 97/103 mg, respectively

Drug: Sacubitril/valsartan
50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.
Other Names:
  • LCZ696; Entresto; Vymada
Active Comparator: Enalapril

Enalapril 10 mg b.i.d.

Following randomization, patients will receive the enalapril in titrated doses from level 1 up to level 3 (2.5, 5 and 10 mg twice daily).

Drug: Enalapril
5 mg and 10 mg will be available for dose adjustments.
Other Names:
  • Renitec
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Hierarchical composite endpoint composed of time to CV death, time to first HF hospitalization, relative change in NT-proBNP from baseline to Week 12
[ Time Frame: Total follow up time up to approximately 36 months ]

The primary efficacy endpoint will be analyzed using the win ratio approach comparing every participant in the sacubitril/valsartan arm to every participant in the enalapril arm to determine a winner. The estimated win ratio (the total number of winners in the sacubitril/valsartan arm divided by the total number of winners in the enalapril arm) will be provided. A winner in the pair-wise comparison has a delayed time to the occurrence of CV death; if time to the occurrence of CV death is censored, a winner has a delayed time to the occurrence of first HF hospitalization event; if the times to both CV events are censored, a winner has a more favorable (less increase or more decrease) change in NT-proBNP between Baseline and Week 12.
Secondary Outcome Measures:
1. Time to the first occurrence of a composite of CV events
[ Time Frame: From the date of randomization to the first occurrence (total follow up time up to approximately 36 months) ]

Time from randomization to the first occurrence of HF hospitalization or CV death
2. Time to all-cause mortality
[ Time Frame: From date of randomization until the date of death from any cause assessed up to the end of the study, which is estimated to be up to approximately 36 months ]

The time to all-cause mortality will be determined.
3. Time to sudden death or resuscitated sudden cardiac arrest
[ Time Frame: From date of randomization until the date of the sudden death or resuscitated sudden cardiac arrest assessed up to the end of the study, which is estimated to be up to approximately 36 months ]

The time to sudden death or resuscitated sudden cardiac arrest will be determined.
4. Number of visits to an ER due to HF (where intravenous therapy is required)
[ Time Frame: From the date of randomization up to End of Study (EOS) assessment. Total follow up time up to approximately 36 months. ]

The rate of visits to an emergency room (ER) due to HF (where intravenous therapy is required) will be determined.
5. Number of days alive out of the hospital
[ Time Frame: From the date of randomization up to End of Study (EOS) assessment. Total follow up time up to approximately 36 months. ]

The number of days alive out of the hospital will be determined.
6. Number of ventricular fibrillation or sustained ventricular tachycardia
[ Time Frame: From the date of randomization up to End of Study (EOS) assessment. Total follow up time up to approximately 36 months. ]

The number of ventricular fibrillation or sustained ventricular tachycardia needing specific pharmacological, electrical or other treatment will be determined.
7. Number of anti-tachycardia pacing or shock therapies
[ Time Frame: From the date of randomization up to End of Study (EOS) assessment. Total follow up time up to approximately 36 months. ]

This will be determined in a subset on a subset of participants who have an ICD or CRT-D at Randomization.
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Key Inclusion Criteria:

  • Male or female ≥ 18 years of age
  • Diagnosis of NYHA Class II-IV HFrEF established by:
    1. LVEF ≤ 40% within 12 months prior to Visit 1 made by any local measurement using echocardiography, multiple gated acquisition scan (MUGA), computerized tomography (CT) scanning, magnetic resonance imaging (MRI), or ventricular angiography, provided no subsequent measurement above 40% AND
    2. NT-proBNP ≥ 600 pg/mL (or BNP ≥ 150 pg/mL) at Visit 1 OR
    3. NT-proBNP ≥ 400 pg/mL (or BNP ≥ 100 pg/mL) at Visit 1 and a hospitalization for HF within the last 12 months
  • Chagas' disease diagnosis confirmed by at least 2 different serological tests for anti-Trypanosoma cruzi (enzyme-linked immunosorbent assay [ELISA], indirect immunofluorescence [IFI], and indirect hemagglutination [IHA]). If documented history is not available, the tests may be performed during the screening.

Key Exclusion Criteria:

  • Patients with history of suspected or proven angioedema or unable to tolerate ACEIs or ARBs (e.g., due to cough, hypotension, renal dysfunction, hyperkalemia)
  • Previous use of sacubitril/valsartan
  • Patients requiring continuous intravenous inotropic therapy or with indication of advanced support intervention for HF:
    1. already on list for a heart transplantation
    2. with current indication of left ventricular assist device, or cardiac resynchronization therapy (CRT)
  • Systemic systolic blood pressure lower than 95 mmHg or symptomatic hypotension
  • Serum potassium > 5.2 mmol/L
  • Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 of body surface area
  • Known gastrointestinal form of chronic Chagas' disease: demonstrated megaesophagus; important megacolon
  • Clinical conditions or systemic diseases limiting proper patient participation
  • Pregnant or nursing women or women of child-bearing potential unless they are using highly effective methods of contraception
  • Presence of other cardiac conditions:
    1. Previous cardiac surgery
    2. Heart failure where, in the Investigator's judgement, there is a possible alternative primary etiology e.g., due to coronary artery disease, valve disease, congenital heart disease or other causes.
    3. Untreated arrhythmia or serious conduction disease e.g., bradyarrhythmias, atrial fibrillation with rapid ventricular response, second or third degree atrioventricular block, etc.
    4. Primary uncorrected valvar pathology like moderate to severe aortic stenosis, mitral stenosis and primary mitral regurgitation
    5. Planned organ transplantation (or in listing for transplantation), planned cardiac or other major surgery (including ventricular assist device implantation)
  • History of malignancy of any organ system within the past 5 years.
Open or close this module Contacts/Locations
Central Contact Person: Novartis Pharmaceuticals
Telephone: 1-888-669-6682
Email: Novartis.email@novartis.com
Central Contact Backup: Novartis Pharmaceuticals
Telephone: +41613241111
Study Officials: Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Locations:
Open or close this module IPDSharing
Plan to Share IPD: Yes

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Supporting Information:
Time Frame:
Access Criteria:
URL:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services